Skip to content

Immix Biopharma, Inc. IMMX Cash Flow Statement

TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
-$34.94M-67.1%-$29.4M-35.5%-$23.56M-6.9%-$23.13M-20.2%-$20.91M-13.5%
$299.17K+339%$245.75K+646%$214.24K+1,290%$122.7K+981%$68.08K+754%
$2.15M-27.0%$2.44M-19.2%$2.58M-23.4%$2.84M-15.7%$2.95M-7.3%
-$32.07M-158%-$23.93M-64.0%-$14.38M+9.0%-$12.51M+15.8%-$12.45M+5.0%
$697.7K-26.1%$732.93K-37.8%$1.07M+57.2%$974.04K$943.48K
-$11.95M-1,166%-$7.21M-513%-$1.07M-57.2%-$974.04K-$943.48K
$63.33M$76.25M
-$32.77M-145%-$24.66M-56.4%-$15.45M+6.2%-$13.48M-$13.4M

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Immix Biopharma, Inc. generate?
Immix Biopharma, Inc. (IMMX) generated -$32.1M in operating cash flow over the trailing twelve months.
What is Immix Biopharma, Inc.'s free cash flow?
After $697.7K of capital expenditures, Immix Biopharma, Inc.'s free cash flow was -$32.8M over the trailing twelve months, down 144.6% year over year.
Where does Immix Biopharma, Inc.'s cash flow data come from?
Every line is extracted from Immix Biopharma, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.